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Abstract
Human dental pulp is a promising alternative source of stem cells for cell-based tissue engineering in regenerative
medicine, for the easily recruitment with low invasivity for the patient and for the self-renewal and differentiation potential
of cells. So far, in vitro culture of mesenchymal stem cells is usually based on supplementing culture and differentiation
media with foetal calf serum (FCS). FCS is known to contain a great quantity of growth factors, and thus to promote cell
attachment on plastic surface as well as expansion and differentiation. Nevertheless, FCS as an animal origin supplement
may represent a potential means for disease transmission besides leading to a xenogenic immune response. Therefore,
a significant interest is focused on investigating alternative supplements, in order to obtain a sufficient cell number for
clinical application, avoiding the inconvenients of FCS use. In our study we have demonstrated that human serum (HS) is
a suitable alternative to FCS, indeed its addition to culture medium induces a high hDPSCs proliferation rate and improves
the in vitro osteogenic differentiation. Furthermore, hDPSCs-collagen constructs, pre-differentiated with HS-medium in vitro
for 10 days, when implanted in immunocompromised rats, are able to restore critical size parietal bone defects. Therefore
these data indicate that HS is a valid substitute for FCS to culture and differentiate in vitro hDPSCs in order to obtain
a successful bone regeneration in vivo.
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Introduction
Research in cell-based tissue engineering has been recently
focused on identifying a cell source suitable for being applied in
regenerative medicine. Dental pulp stem cells (DPSCs), discovered
in human dental pulp even in young adults, are clonogenic cells
capable of both self-renewal and multiple lineage differentiation
[1]. DPSCs can be stimulated to differentiate, under specific
conditions, towards various cell types, such as adipocytes,
myoblasts, neurons, chondrocytes and osteoblasts [2–4]. Their
wide range of differentiation allows them to represent a promising
tool for reconstructive medicine, replacing lost or damaged tissues.
This property may be related to the neural crest-cell origin of the
dental pulp. It constitutes an adequate alternative source of stem
cells for the easily recruitment with low invasivity for the patient
and for the differentiation potential of its cells [5–6].
It has been shown that dental pulp stem cells proliferate and
produce an extracellular matrix which subsequently becomes
mineralized in vitro [5]. Recent studies have demonstrated that
hDPSCs, after in vitro differentiation with an osteogenic medium,
can differentiate into osteoblasts and produce mineralized
extracellular matrix, both in 2D cultures and in 3D different
biomaterials and, when implanted in immunocompromised
animals produce bone and restore critical size bone defects [7–12].
In vitro culture of mesenchymal stem cells is based on
supplementing cell culture and differentiation media with foetal
calf serum (FCS). As it contains a great number of growth factors,
FCS promotes cell attachment to plastic surfaces as well as cell
proliferation and differentiation. Nevertheless, using FCS may
trigger a xenogenic immune response and immunological reac-
tions once cell transplantation in humans has been done [13–15].
This reason supports the attempt to evaluate MSCs culture and
differentiation in media containing alternative supplements to
FCS. Previous data report that human platelet lysate can replace
FCS in terms of clinical-scale expansion [16–17] and in vivo bone-
forming capacity of human stromal MSCs [18]. Felka et al. [19]
demonstrated that human plasma represents a suitable replace-
ment to FCS for expansion and differentiation of adipose derived
stem cells. Human serum is also a suitable alternative, due to its
availability and possibility for testing for human pathogens before
use [17,20].
In this study we have modified the expansion and differentiation
media by replacing FCS with human serum (HS), to evaluate and
compare the osteogenic phenotype developed by a sub-population
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of hDPSCs positive to STRO-1 antigen. In particular we analyzed
the typical markers of the osteogenic differentiation, such as
mineralized matrix production, alkaline phosphatase activity and
osteopontin, osteocalcin, collagen type I expression. Finally, we
have evaluated the hDPSCs ability of producing bone and
restoring critical size bone defects when implanted in vivo in
association with collagen scaffold.
Materials and Methods
Preparation of Human Serum
Human serum was obtained from a blood collection by healthy
male volunteers who underwent written informed consent. The
whole blood was drained into 8 ml tubes containing silica beads
for clot activation (Greiner Bio-one, Kremsmu¨nster, Austria), then
was stored at room temperature for 3 hours and centrifuged at
14006g for 15 minutes, to separate erythrocytes and coagulum
contents. The collected serum was heat inactivated at 56uC for 30
minutes, then filtered with a 0.22 mm syringe-driven filters units
(Millipore; Billerica, MA, USA). Aliquots of sterile human serum
were stored at 220uC.
Cell Culture
Human dental pulp was extracted from the enclosed third
molar of teenage subjects undergoing a routine tooth extraction,
after written informed consent of their parents. All procedures
regarding collection of human samples were approved by the
Provincial Ethics Committee of Santa Maria Nuova Hospital of
Reggio Emilia. hDPSCs were isolated from dental pulp, as
described in a previous study [8]. Briefly cells obtained from dental
pulp were plated at clonal density (1.6 cells/cm2) and after 6 days
of culture, nodules originated by single cells were isolated from the
culture plate, re-plated and expanded. The STRO-1+ hDPSCs
were obtained by magnetic cell sorting (MACS; Miltenyi Biotec)
using an anti-STRO-1 antibody (Ab; Santa Cruz). Two different
culture media were used during isolation steps and in the
successive cultures: a-MEM supplemented with heat inactivated
10% Foetal Calf Serum (FCS-medium; Euroclone) or Human
Serum (HS-medium), 2 mM L-glutamine, 100 U/ml penicillin,
100 mg/ml streptomycin, at 37uC and 5% CO2.
Cell Counting
The proliferation rate was analyzed on the same hDPSCs
population, seeded in 60 mm Petri dishes at the density of 46103
cells/cm2 and cultured for 1 week until reaching the confluence.
Cell counting was performed in three culture conditions: serum
free culture medium; culture medium supplemented with FCS;
culture medium supplemented with HS. Each day cells were
stained with CFDA (6-Carboxyfluoresceine diacetate, Sigma
Aldrich; St. Louis, MO, USA) vital dye to detect viable cells and
observed by using a Nikon TE2000 inverted microscope with
a 106 objective. For each experimental point, green fluorescent
cells contained in 10 fields of 1 mm2 were counted. The mean of
cell number was calculated on three experimental samples for each
condition and cell density was expressed as mean of cells/cm26
standard deviation (SD). The population doubling time (PDT) was
calculated in the phase of exponential growth by the following
formula:
PDT~
log10(2)|DT
log10(N7d ){log10(N1d )
N7d is the cell number at day 7 and N1d is the cell number at day
1.
To determine the population doubling (PD) rate, hDPSCs were
initially seeded at the density of 46103 cells/cm2 in culture
medium supplemented with FCS or HS. Cells were passaged and
counted once they reached a sub-confluence of 80%. At each
passage cell were re-plated at the initial density and culture were
performed until passage 5. Three samples for each condition were
used. The following formula was applied:
PD~
log10(N){log10(Ns)
log10(2)
N is the harvested cell number and Ns is the initial plated cell
number. Cumulative population doublings (CPD) index for each
passage was obtained by adding the PD of each passage to the PD
of the previous passages.
Clonogenicity, Senescence and Cell Death
In order to evaluate colony forming ability, hDPSCs cultured in
HS-medium and in FCS-medium were seeded at clonal density
(1.6 cells/cm2) in 6-well plates and cultured for 10 days. Six
samples for each culture condition were fixed in 4% para-
formaldehyde in phosphate buffered saline (PBS) and stained with
Toluidine blue. Counting was performed considering only colonies
consisting of more than 10 cells.
In order to evaluate the presence of senescent cells in hDPSCs
maintained in HS-medium and in FCS-medium, cells at 5th
passage were seeded in 12-well plates and cultured until reaching
the confluence. Samples were then processed by a senescence b-
Galactosidase staining kit (Cell Signaling), according to manufac-
turer’s instructions. Three samples for each culture condition were
analyzed and percentage of senescent cells was calculated.
The presence of apoptotic cells in hDPSCs cultures was
analyzed by detection of the cleaved form of poli(ADP-
ribose)polymerase (PARP). Whole cell lysates of hDPSCs cultured
in HS-medium and in FCS-medium at passages 1, 3 and 5 were
processed for Western blot analysis and PARP was detected by an
anti-PARP specific Ab (Santa Cruz).
FACS analysis. Isolated hDPSCs cultured for 5 passages in
FCS-medium and HS-medium were assayed for the expression of
Stro-1, c-Kit and CD34 surface antigens. Indirect staining was
performed using mouse anti-STRO-1 IgM, rabbit anti-c-Kit IgG
(Santa Cruz) and mouse anti-CD34 IgG (Millipore), followed by
goat anti-mouse-IgG-Alexa488, goat anti-rabbit-IgG-Alexa488;
and goat anti-mouse-IgM-Alexa488 (Invitrogen). Non-specific
fluorescence was assessed by using normal mouse IgG or IgM
followed by the secondary antibody as described above. Samples
were analyzed using a 16-parameters CyFlow ML flow cytometer
(Partec GmbH, Munster, Germany), equipped with a 488-nm blue
solid-state, a 635-nm red diode laser, a UV mercury lamp HBO,
a 532-nm green solid state laser, a 405-nm violet laser, and a CCD
camera. Data were acquired in list mode by using FloMax (Partec)
software, and then analyzed by FlowJo 9.4.11(Treestar Inc., Ash-
land, OR) under MacOS 10. A minimum of 20,000 cells per
sample were acquired.
In vitro Multilineage Differentiation
hDPSCs cultured in HS-medium and FCS-medium were tested
for their ability to differentiate towards Neurogenic, Adipogenic
and Myogenic lineages. Three samples of each culture condition
were used for each differentiation experiment.
HS for hDPSC Growth and Osteogenic Differentiation
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Myogenic differentiation experiments were carried out accord-
ing to Laino et al. [21]. For investigating the capability of hDPSCs
to participate in myotubes formation, cells were seeded in direct
co-culture with C2C12 mouse myoblast cell line. Human DPSCs
and C2C12 cells were seeded in a 10:1 ratio in DMEM High
Glucose, supplemented with 10% FBS or HS, 2 mM L-glutamine,
100 U/ml penicillin, 100 mg/ml streptomycin, until confluence
was reached. Upon confluence, growth medium was replaced with
DMEM High Glucose supplemented with 1% FBS or HS and
10 nM insulin. Cells were maintained in co-culture for 2 weeks.
Double immunofluorescence staining, by using an anti-human
mitochondrial protein Ab (anti-hMit; Millipore, Billerica, MA,
USA) and an anti-Myosin Ab (SIGMA), was performed in order to
verify the formation of myotubes with the direct contribution of
hDPSCs.
Neurogenic and Adipogenic differentiation were performed as
described by Zang et al [22]. Neurogenic differentiation: cells were
seeded on 6-well plates at 20,000 cells/cm2. After confluency was
reached, cells were pre-induced with FCS-medium or HS-medium
supplemented with 1 mM b-mercaptoethanol. After 24 h, the cells
were washed and differentiated in serum free aMEM containing
10 mM b-mercaptoethanol, 2% dimethyl sulfoxide and 200 mM
butylated hydroxyanisole until neuronal morphology was detect-
able. Neuronal differentiation was assayed for expression of b3-
Tubulin by immunofluorescence experiments using specific Ab
(Cell Signaling).
Adipogenic differentiation: cells were seeded on 24-well plates at
20,000 cells/cm2. Subconfluent cultures were incubated in the
adipogenic medium (FCS-medium or HS-medium containing
0.5 mM isobutyl-methylxanthine, 1 mM dexamethasone, 10 mM
insulin, 200 mM indomethacin, 50 mg/mL gentamicin) for 3
weeks. Medium was changed every 3 days. Afterwards, cells were
stained with oil red O stain and counterstained with Harris
haematoxylin.
In vitro Osteogenic Differentiation
In order to obtain osteogenic differentiation on 2D surface,
STRO-1+ hDPSCs were seeded at approximately 36103 cells/
cm2 on culture dishes in two different osteogenic media (culture
medium supplemented with 100 mM 2P-ascorbic acid, 100 nM
dexamethasone, 10 mM b-glycerophosphate) containing 5% FCS
(FCS-osteogenic medium) and 5% HS (HS-osteogenic medium),
respectively. In particular hDPSCs cultured in HS-medium were
differentiated in HS-osteogenic medium while cells cultured in
FCS-medium were differentiated in FCS-osteogenic medium. The
media were changed twice a week.
Collagen sponges (Condress, ABIOGEN PHARMA S.p.A.)
were used as 3D scaffold in this study, for the subsequent in vivo
implantation. Cells were seeded in collagen sponge samples
(13 mm diameter; 1.5 mm height), into a 12 multiwell plate, in
an adequate volume of culture medium to obtain a starting density
of about 16106 cells per sponge. After 8 hours from cell seeding,
2 ml of the two osteogenic media were added to each sample.
hDPSCs/collagen constructs were pre-differentiated for 10 days
before in vivo implantation according to previous data [8,10].
Surgery and Implantation Procedure
The in vivo implantation has been realized in 14 weeks old
Sprague-Dawley male rats and surgical procedure was performed
as described by Riccio et al. [10].
In order to compare the bone forming ability of hDPSCs on
collagen scaffolds in both pre-differentiation conditions, a critical
size bone defect was generated by a full-thickness dissection of
both the internal and external tables of compact bone constituting
the parietal skeletal segment. The stem cell-scaffold complexes
were then implanted into the critical size parietal defect up to 6
weeks.
One scaffold 56861.5 mm size was implanted into each cranial
defect and adapted to fill the entire defect area; each animal
received two constructs: on the left parietal bone the construct pre-
differentiated with FCS-osteogenic medium; on the right parietal
bone the construct treated with HS-osteogenic medium. Control
group received only collagen scaffold. Six weeks after the surgical
implantation the rats were sacrificed and the calvarias were rapidly
explanted and fixed in 4% paraformaldehyde in PBS for 3 h.
A total of 10 animals were used in this study (controls n= 4;
treated n= 6). All animal procedures were performed according to
the guidelines approved by the Committee of Use and Care of
Laboratory Animals of the University of Modena e Reggio Emilia.
Histology, Histochemistry and Morphometry
Some samples of in vitro differentiated hDPSCs were fixed in 4%
paraformaldehyde in phosphate buffered saline (PBS) at pH 7.4
for 20 minutes and were processed for subsequent steps. For
Alizarin red staining fixed cells were incubated for 5 minutes at
room temperature in a solution containing 0,1% alizarin red and
1% ammonium hydroxide. Other samples were fixed in methanol-
acetone 3:7 for 10 minutes at 220uC, in order to perform the
alkaline phosphatase assay. For this enzymatic assay fixed cells
were processed by using Leukocyte Alkaline Phosphatase Kit
(Sigma Aldrich; St. Louis, MO, USA), following the manufac-
turer’s instructions. Images were collected by a CCD colour
camera equipped with a 90 mm macro photograph objective.
Densitometry was performed on culture plates from three
independent experiments by NIS software (Nikon). An equal area
(ROI) was selected around the plate surface and the mean of gray
levels (in a 0–256 scale) was calculated. Data were then normalized
to values of background and expressed as mean 6 SD.
Fixed samples of explanted calvarias were immersed in
0.5 M EDTA pH 8.3 until the complete decalcification and then
rinsed in PBS, dehydrated with graded ethanol, diaphanized and
embedded in paraffin. Transversal serial sections (10 mm thick) of
the parietal bones containing the implants, were cut. Routine
haematoxylin/eosin (H & E) staining was performed in order to
analyze morphological details. Images of histological samples were
obtained with a Nikon Labophot-2 optical microscope equipped
with a DS-5Mc CCD color camera.
Morphometry on regenerating bone areas was performed by
NIS software (Nikon). Implant area and new-formed bone area
were measured in 5 transversal sections of implanted parietal bone
for each animal. Percentage of new-formed bone was calculated
respect to the total area of implant. Vasa, identified by
morphological criteria and by labeling with anti-von Willebrand
factor Ab, were counted in the area of not yet reabsorbed scaffold
and in the area of new-formed bone for each animal and for each
implant type. Data were normalized to areas of not yet reabsorbed
scaffold and of new-formed bone respectively and were presented
as mean 6 SD of each experimental group (controls n = 4; treated
n= 6).
Confocal Miscroscopy
Fixed monolayer cells were permeabilized with 0,1% Triton X-
100 in PBS for 5 minutes; samples were then blocked with 3%
BSA in PBS for 30 minutes at room temperature and then
incubated with the primary antibodies diluted 1:50 [rabbit anti-
osteocalcin (OCN), mouse anti-osteopontin (OPN), rabbit anti-
osterix (Osx), rabbit anti-Runx2, mouse anti-hMit, rabbit-anti
myosin, mouse anti b3-Tubulin] in PBS containing 3% BSA, for 1
HS for hDPSC Growth and Osteogenic Differentiation
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hour at room temperature. After washing in PBS containing 3%
BSA, the samples were incubated for 1 hour at room temperature
with the secondary antibodies diluted 1:200 in PBS containing 3%
BSA (goat anti-rabbit FITC, sheep anti-mouse FITC, donkey anti-
rabbit Cy3). After washing in PBS samples were stained with
1 mg/ml DAPI in PBS for 1 minute, and then mounted with anti-
fading medium (0.21 M DABCO and 90% glycerol in 0.02 M
Tris, pH 8.0).
Histological sections were processed as previously described by
Riccio et al [10]. Primary antibodies (mouse anti-hMit, rabbit
anti-OCN, Millipore; rabbit anti-von Willebrand factor, SIGMA)
were diluted 1:80 in PBS containing 3% BSA for 1 hour at room
temperature. Secondary antibodies were diluted 1:200 in PBS
containing 3% BSA (goat anti-mouse alexa488, goat anti- rabbit
alexa546, Life Technologies; Carlsbad, CA, USA). Negative
controls were samples not incubated with the primary antibody.
The multi-labelling immunofluorescence experiments were carried
out avoiding cross-reactions between primary and secondary
antibodies.
Immunohistochemistry with ant-hMit revealed by an anti-
mouse HRP labelled secondary Ab (Pierce) was performed in
order to confirm specificity of the labelling. HRP was revealed by
a DAB based kit (SIGMA). Control without primary Ab was also
performed.
Fluorescent samples were observed by a Nikon A1 confocal
laser scanning microscope as described below. For detection, the
samples were sequentially excited with the respective laser
wavelength: 405 nm lines of a diode laser for DAPI; 488 nm
lines of the argon laser for FITC or alexa488; 543 nm line of
a HeNe laser for Cy3 or alexa546. The excitation and the
detection of the samples were carried out in sequential mode to
avoid overlapping of the two signals. Optical sections were
obtained at increments of 0.3 mm in the z-axis and were digitized
with a scanning mode format of 102461024 pixels and 4096 gray
levels.
Spectral analysis was carried out to exclude overlapping
between two signals or the influence of autofluorescence on the
fluorochrome signals. Spectral imaging was carried out by
simultaneous excitation of fluorochromes in the middle serial
optical sections of the sample. Emission signals were acquired by
a 32 line spectral detector and the full spectral emission was
considered without any image elaboration. Moreover, ROIs were
tracked on the images and the relative emission spectra were then
analyzed. Spectra profiles were visualized in a wavelength range
comprising the theoretical emission spectra of the fluorochromes
present in the sample. In correspondence of the excitation laser
wavelength the emission spectra show an unreal trend to zero
because the correspondent line of the spectral detector was
automatically turned off in order to avoid photomultiplier
damages.
The confocal serial sections were processed with ImageJ
software to obtain three-dimensional projections and image
rendering was performed by Adobe Photoshop Software.
Western Blot
Whole cell lysates were obtained at different times of
differentiation by using an hypotonic buffer (30 mM Tris-Cl,
pH 7.8, containing 1% Nonidet P40, 1 mM EDTA,
1 mM EGTA, 1 mM Na3VO4, and freshly added Sigma-Aldrich
Protease Inhibitor Cocktail). Lysates were cleared by centrifuga-
tion and the total lysate was immediately boiled in SDS sample
buffer. The protocols of the Western blot were performed as
described by Sambrook et al [23]. Sixty mg of protein extract,
quantified by a Bradford Protein Assay (Biorad), underwent SDS-
polyacrylamide gel electrophoresis and were transferred to PVDF
membranes. The following antibodies were used: rabbit anti-
osteocalcin antibody diluted 1:500; mouse anti-collagen type I
(Millipore; Billerica, MA, USA), rabbit anti-PARP (Santa Cruz)
diluted 1:1000; peroxidase-labelled anti-rabbit and anti-mouse
secondary antibodies diluted 1:3000 (Pierce Antibodies, Thermo
Scientific; Rockford, IL, USA). Antibody dilution was performed
in TBS-T pH 7.6 containing 2% BSA and 3% free fatty milk. The
membranes were visualized using ECL (enhanced chemiolumines-
cence, Amersham, UK). Anti-actin antibody was used as control of
protein loading. Densitometry of cleaved PARP bands was
performed by NIS software (Nikon). An equal area was selected
inside each band and the mean of gray levels (in a 0–256 scale) was
calculated. Data were then normalized to values of background
and of control actin band.
Statistical Analysis
All experiments were performed in triplicate. Quantitative or
semi-quantitative data were expressed as mean 6 standard
deviation (SD). Differences between two experimental points or
between experiments were evaluated by paired Student’s t-test.
ANOVA test followed by Bonferroni post-test was used to analyze
differences between three or more experimental points. In all
analyses, values of p,0.01 were considered a significant statistical
difference, while values of p,0.001 were considered a strong
significant statistical difference.
Results
Cell Proliferation
To evaluate the influence of HS or FCS on the growth of
hDPSCs during routine cell culture, proliferation rate was
evaluated by using 6-CFDA staining to detect viable cells in
adherent culture at different times until confluence was reached.
hDPSCs were then grown in culture media without serum or
containing respectively 10% FCS and 10% HS, and cell counting
was performed for up to 7 days (Fig. 1A). Human DPSCs cultured
in serum free medium show a not significant proliferation rate
indicating a stationary trend. Cells cultured with HS show, at the
beginning, a slightly lower proliferation rate compared to hDPSCs
growing in FCS-medium. From day 4 onward the proliferation
rate of cells in HS-medium slightly exceeds, in significant manner,
the one of hDPSCs growing in FCS-medium (Fig. 1B). Further-
more the population doubling time of HS cultures is lower than
FCS cultures (HS: 35.062.31 hours; FCS: 40.361.50 hours;
p,0.01). Cumulative population doubling analysis shows that HS
culture proliferates more speedily, overtaking FCS culture of about
13% at each passage (Fig. 1C).
hDPSCs cultured in HS-medium or in FCS-medium for 5
passages were seeded at clonal density and cultured in 6-well
culture plates for 10 days in order to verify differences in
clonogenic ability. No significant differences were observed in the
number of colonies formed by hDPSCs growing in the two culture
conditions (HS 17.364.8 colonies; FCS 18.764.0 colonies).
Senescence and Apoptosis
Cell senescence was evaluated by detection of b-galactosidase
activity in confluent culture of hDPSCs grown for 5 passages in
HS-medium or in FCS-medium. Very low levels of b-galactosidase
activity were detected in both culture conditions (Fig. 1D arrow-
heads). In particular no significant differences were observed in the
percentage of senescent cells detected by microscopic observation
in the two culture conditions (FCS 0.04460.007%; HS
0.03960.004%; n= 3).
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Western blot analysis of PARP carried out in hDPSCs at
passages 1, 3 and 5, shows an equivalent amount of uncleaved
PARP (116 kDa) in both culture conditions. On the other hand
positive control, (etoposide treated HL60 cell line) shows a clear
band in correspondence of cleaved PARP form (89 kDa; Fig. 1E)
that is not appreciable in hDPSCs. Densitometry performed on
the cleaved PARP bands did not show significant differences
between HS and FCS cultured DPSCs.
These data indicate that HS-medium does not induce pre-
mature senescence and does not affect the survival of hDPSCs.
Surface Antigens Expression and in vitro Multilineage
Differentiation
In order to verify if HS influences stemness of hDPSCs during
in vitro culture, surface antigens expression and multilineage
differentiation ability were evaluated in hDPSCs cultured in HS-
medium and in FCS-medium.
Stro-1, c-Kit, and CD34 are surface antigens typical of hDPSCs
[21]. FACS analysis performed in hDPSCs in both culture
conditions after 5 passages, demonstrates that hDPSCs maintain
the expression of the above mentioned antigens. Moreover, the
fluorescence intensity of c-Kit labelling appears higher in HS-
cultures, indicating that the whole population expresses this
antigen at a dim level. Stro-1 and CD34 antigens appear equally
expressed (Fig. 2A).
hDPSCs cultured in both media were differentiated towards
myogenic, adipogenic, neurogenic and osteogenic lineages as
described in materials and methods.
The ability of hDPSCs to differentiate towards myogenic
lineage was verified by co-culture with C2C12 mouse myoblasts.
After 14 days of co-culture myotubes formation was observed both
in HS co-cultures and in FCS co-cultures. Myotubes appear multi-
nucleated indicating that cell fusion occurs. Labelling by anti-
human mitochondria antibody (anti-hMit) demonstrates that
hDPSCs are involved in myotubes generation. Double staining
with anti-hMit and anti-myosin antibodies indicates that in both
culture conditions mature myotubes were formed with the
contribution of hDPSCs. Myotubes not labelled by anti-hMit
antibody and therefore formed only by C2C12 cells were also
present (Fig. 2B). The percentage of myotubes formed with the
contribution of hDPSCs respect to the total myotubes, was similar
in both culture conditions (FCS 42,766,4%; HS 46,367,2%;
n= 3).
hDPSCs cultured in adipogenic medium supplemented with HS
start to form intracellular lipidic drops after three days of
differentiating culture while cells differentiating in FCS adipogenic
medium show the first intracellular lipidic drops at the 7th day.
After two weeks of differentiation, hDPSCs in both conditions
Figure 1. hDPSCs growing in FCS, HS and serum free (SF)
media. A: CFDA vital staining of hDPSCs cultured for 1, 4 and 7 days.
Green signal indicates viable cells. Bar: 100 mm. B: Proliferation rate of
hDPSCs cultured for a week; Values are mean reported in a Log scale,
n = 3; * indicates values of paired t-test HS vs. FCS (**p,0.01,
***p,0.001). C: Cumulative population doubling (CPD) of hDPSCs
cultured for a total of 5 passages. At each passage cells cultured in HS-
medium show a CPD significantly higher than FCS-medium cultured
cells (n = 3; ***p,0.001). D shows b-galactosidase activity staining in
confluent culture of hDPSCs grown for 5 passages in FCS-medium or in
HS-medium as indicated. Arrowheads indicate cells positive to b-
galactosidase activity staining. Bar 10 mm. E: western blot analysis of
PARP in hDPSCs cultured in FCS-medium and in HS-medium at
passages 1, 3 and 5. HL60, treated with etoposide, were loaded as
positive control of the presence of cleaved PARP (cPARP). Actin bands
were presented as control of the protein loading. Densitometry of
cPARP bands was shown on the bottom of western blot images.
doi:10.1371/journal.pone.0050542.g001
HS for hDPSC Growth and Osteogenic Differentiation
PLOS ONE | www.plosone.org 5 November 2012 | Volume 7 | Issue 11 | e50542
show a similar morphology characterized by numerous lipidic
drops accumulated in the cytoplasm and clearly stained by oil red
(Fig. 2B). The percentage of oil Red positive cells did not show
significant differences between the two culture conditions (FCS
73,768,1%; HS 75,769,0%; n= 3).
Neurogenic differentiation starts with an initial cell detachment
from culture plates probably induced by b-mercaptoethanol.
Remaining cells progressively assume neuronal morphology with
multiple cellular processes and a defined cell body. Immunostain-
ing with anti-b3-Tubulin after 20 days of culture shows the
presence of neurotubules in hDPSCs pre-differentiated in FCS-
medium as well as in HS-medium (Fig. 2B). No particular
differences, in the percentage of b3-Tubulin positive cells, were
observed between the two experimental groups (FCS 64,367,2%;
HS 62,067,6%; n= 3).
Osteogenic differentiating hDPSCs start to form nodular
aggregates at day 8. At day 24, mineral deposits appear in the
extracellular space and in nodular aggregates (data not shown). In
cells, both the differentiation conditions induce an intense
positivity to Alkaline phosphatase assay, which is extended to the
whole culture plate. The in vitro deposition of mineralized
extracellular matrix was analyzed by Alizarin red staining:
differences were observed in Alizarin red staining, in favour of
hDPSCs treated with HS (Fig. 3A), which show a greater
deposition of mineralized extracellular matrix than hDPSCs
differentiated with FCS, as confirmed by densitometric analysis.
A higher alkaline phosphatase activity was detected in HS-treated
cells (Fig. 3B). Controls of undifferentiated cells are negative for
both the stainings (Fig. 3A).
The confocal analysis at day 24 shows the expression of
osteocalcin, together with other specific markers of osteogenic
commitment, such as osteopontin (OPN), osterix (Osx) and
Runx2. Double immunofluorescence labelling was carried out to
analyze simultaneously the localization of OPN and Runx2 in
hDPSCs differentiated with FCS-medium or HS-medium
(Fig. 3C). OPN appears localized in the cytoplasm perinuclear
region, that normally contains the rough endoplasmic reticulum,
while Runx2 is localized in the cell nucleus as expected. OCN
shows a typical cytoplasmic localization, strongly expressed in both
the differentiation conditions. Signal from OCN was also detected
in extracelluar matrix where it appears as spot localized in
mineralization areas. Similarly to Runx2, Osx shows the typical
nucleoplasmic localization, as demonstrated by the overlapping
with DAPI signal (Fig. 3C). No differences were observed between
the two differentiation conditions.
To confirm the differentiation of hDPSCs towards osteoblast-
like cells, in both osteogenic media, the presence of type I collagen
(Coll-I) and of the specific marker osteocalcin (OCN), was
Figure 2. hDPSCs surface antigens expression and in vitro
multilineage differentiation ability. A: Cytofluorimetric analysis of
Stro-1, c-Kit and CD34 expression in hDPSCs cultured in FCS-medium
and in HS-medium. Dot plots reporting SSC vs fluorescence are shown.
In the histograms, the net fluorescence value was calculated by
linearizing the fluorescence value from the logarithmic scale and
subtracting the linearized value of the unstained sample to the
linearized value of the stained one. Data represent the mean6SD of
three different experiments. * indicates values of paired t-test HS vs. FCS
(*p,0.05). B: In the first line are shown double immunofluorescence
images of hDPSCs/C2C12 co-culture stained by anti-hMit (green) and
anti-myosin (red) Abs. DAPI staining is shown in blue. The second line
shows oil red staining of hDPSCs differentiated for two weeks towards
adipogenic lineage with HS or FCS supplemented medium. Cells were
counterstained with Harris haematoxylin. Images, in third line represent
anti-b3-Tubulin immunofluorescence labelling on hDPSCs differentiated
in culture neurogenic media supplemented with FCS or HS. Bar 50 mm.
doi:10.1371/journal.pone.0050542.g002
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analyzed by Western blot in whole cell lysates of differentiating
hDPSCs: Coll-I and OCN were detected in both the differenti-
ating conditions, and show an increase of expression during the
differentiation (Fig. 3D).
In vivo Osteogenic Differentiation
In order to evaluate if the use of different sera (FCS and HS)
during pre-differentiation of hDPSCs seeded in collagen scaffold,
influences differently their ability to reconstruct critical size
parietal bone defects, in vivo implants were performed as described
in materials and methods section. After six weeks parietal bones
containing the implants were histologically processed and observed
by white field microscopy.
Figure 4 shows representative photomicrographs of engineered
bone grafts in vivo.
The hDPSCs/collagen constructs realized in both pre-differen-
tiation conditions exhibit an appreciable contribution to re-
generation of the resected bone area (Fig. 4A, 4D). Magnification
images show the presence of vessels indicating a successful
vascularization of the implants (Fig. 4: B–C–E–F, arrowheads)
and areas of active bone deposition and rearrangement, particu-
larly detectable in samples pre-differentiated with osteogenic HS-
medium, where osteoblast layer surrounds islets of new-formed
bone (Fig. 4E, 4F, star). Morphometric analysis was carried out in
order to evaluate the amount of new-formed bone areas in animals
implanted with collagen scaffold colonized with FCS or HS pre-
differentiated hDPSCs and in the control group implanted only
with the collagen scaffold. The analysis revealed that animals
implanted with scaffold colonized with hDPSCs pre-differentiated
in FCS and in HS differentiating medium show a bone re-
generation significantly higher when compared to the control
group (FCS vs C p,0.01; HS vs C p,0.001; Fig. 4G). Moreover,
by comparing HS implants with FCS implants emerges that the
new-formed bone area is greater in HS implants respect to the
FCS implants (HS vs FCS p,0.001; Fig. 4G). The number of vasa
in the scaffold not yet reabsorbed appears higher in HS pre-
differentiated cells suggesting a better angiogenic potential. On the
other hand the number of vasa in new-formed bone does not show
significant differences among the three experimental groups
indicating that the new-formed bone structure was not affected
by the different pre-differentiation conditions (Fig. 4H).
To verify if cells inside the new-formed bone were still from
human origin and not from the host, immunofluorescence
labelling with anti-hMit antibody was performed. This antibody
recognizes only mitochondrial protein from human origin: images
of stem cell-scaffold implants demonstrate that most of the cells are
clearly stained by anti-human mitochondria antibody (Fig. 5 A–D)
indicating survival of the donor cells in vivo, in both the pre-
Figure 3. In vitro osteogenic differentiation of hDPSCs after 24
days of culture in osteogenic medium, supplemented with FCS
or HS. A: Alkaline phosphatase assay (AP) and Alizarin Red staining; B:
densitometric analysis of AP and Alizarin Red staining. Values are mean
6 SD of gray levels (0–255 scale). HS n = 3; FCS n= 3; ** indicate values
of paired t-test HS vs. FCS (p,0.01). C: Confocal analysis of osteogenic
differentiation of hDPSCs. Double immunofluorescence confocal
images showing signals from anti-OPN (green) and anti-Runx2 (red);
DAPI (blue) and anti-OCN (green); DAPI (blue) and anti-Osx (red). Bar:
50 mm. D: Western blot (WB) analysis of Coll-I and OCN expression in
whole cell lysates of differentiated hDPSCs. Whole cell lysates were
collected from three plates of human dental pulp stem cells for each
differentiation protocol. Actin bands demonstrate that an equal amount
of protein was loaded in each line. Undiff samples show hDPSCs
cultured in FCS-medium alone. The same results were obtained in HS-
medium culture (data not shown).
doi:10.1371/journal.pone.0050542.g003
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differentiation conditions. Specificity of anti-hMit immunofluores-
cence labelling was demonstrated in supporting information (Fig.
S1 A–B, E–F) as well as immunoperoxidase reaction confirms the
presence of human cells inside the new-formed bone (Fig. S1 C–
D).
Interestingly, human DPSCs are included within bone lacunae
indicating the direct contribution to the osteocytes population of
new-formed bone. Double immunofluorescence analysis shows
that human cells express OCN that was detectable also in new-
formed bone matrix (Fig. 5 E–H). Moreover cells localized in the
inner layer of vascular canals show a clear staining by anti-human
mitochondria antibody, suggesting a direct contribution of
hDPSCs to the angiogenetic process that originates endothelial
cells of new-formed vasa. Double labelling by anti-hMit and anti-
von Willebrand factor indicates that hDPSCs contribute to the
constitution of the endothelium of vasa localized in the new-
formed bone (Fig. 5 I–L).
Spectral analysis demonstrates the specificity of the double
immunofluorescence labelling (Fig. S1 G–H).
Discussion
In this study we have investigated a culture condition that may
allow human DPSCs for cell-based therapy to be used in clinical
application with minimal safety concerns. This goal assumes it is
desirable and necessary to obtain a sufficient number of cells, as
the result of expansion and differentiation conditions realized by
using the most suitable reagents to promote cell proliferation and
differentiation. FCS has been widely used for this purpose over the
past several decades. Anyway, some potential hazards related to
using FCS in clinical settings have been raised in terms of potential
disease transmission and xenogenic immunologic response [24].
Indeed previous works indicate that FCS proteins can be
internalized in stem cells and involve the hazard of pathogen
transmission: bovine proteins may also be recognized as antigenic
substrates, leading to a xenogenic immune response [14–15]. For
these reasons, in addition to good manufacturing practices (GMP),
clinical protocols for cell therapy encourage the use of FCS
substitute [25].
Even serum free media have been tested, but so far literature
has demonstrated these media do not constitute an adequate
support for proliferation of mesenchymal stem cells, without
addition of exogenous growth factors [26,27]. Supplementation of
media with small amount of serum and specific factor as EGF and
PDGF could represent a valid perspective [28].
Various human plasma derivatives have been purposed as
alternatives to FCS to supply nutrients, adhesion and growth
factors. These alternative supplements include autologous or
allogenic human serum, human plasma, human platelet lysates
and their released factors [16,20,29]. In the last years platelet-rich
plasma was largely used to growth and differentiate MSC but its
role in MSC osteogenic differentiation is debated [30–32]. The use
of human serum, preferably autologous, appears to provide
benefits for different aspects in culture and differentiation of
human synovial MSCs and human bone marrow MSCs [33–35].
Evidence in favour of using autologous serum also exist for the
expansion of human bone marrow MSCs, indeed it results as
Figure 4. Comparative histological analysis (haematoxylin/
eosin staining) of the critical size cranial defect reconstruction
by hDPSCs/collagen constructs 40 days post-surgery. Images
show transversal sections carried out through the central area of the
implants. A–C: cranial defect filled with hDPSCs/collagen pre-differen-
tiated with FCS containing medium; D–F: cranial defect closed with
hDPSCs/collagen pre-differentiated with HS containing medium;
(dotted line delimitates the areas of bone resection; arrowheads
indicate vasa; * indicate areas of active bone deposition). Bar: 100 mm.
G: morphometric analysis of new-formed bone areas in controls (C), FCS
and HS implants. Values are mean 6 SD of the percentage of
regenerated bone respect to the whole resected bone area. HS and FCS
n= 6; C n = 4; white * inside the column indicate values of ANOVA test
of HS and FCS vs. C (**p,0.01, ***p,0.001); black * indicate values of
ANOVA test of HS vs. FCS (***p,0.001). H: number of vasa in the
scaffold not yet reabsorbed and in new-formed bone areas. Data,
normalized to areas of the scaffold not yet reabsorbed and of new-
formed bone areas respectively, were presented as mean 6 SD (vasa
number respect to the total implant area) of each experimental group
(controls n = 4; treated n= 6). White * inside the column indicate values
of ANOVA test of HS and FCS vs. C (***p,0.001); black * indicate values
of ANOVA test of HS vs. FCS (*p,0.05).
doi:10.1371/journal.pone.0050542.g004
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effective as supplementing culture medium with FCS, and cells
appear transcriptionally more stable over many cell doublings
[14]. Nevertheless, autologous serum may also be a scarcely
available or qualitatively affected source, particularly in the case it
must be taken from some classes of patients, such as children,
elderly, anaemic and with ongoing inflammatory processes
individuals [33]. In these cases, allogenic human serum, potentially
from blood type AB healthy donors may represent a preferable
alternative to autologous serum.
To date, human platelet lysate and platelet-rich plasma have
been shown to be suitable culture supplements to replace FCS, for
the expansion and in vitro osteogenic differentiation of hDPSCs
[36,37]. To the best of our knowledge, in literature there is not yet
evidence that human serum may constitute a suitable replacement
to FCS for culture and differentiation of human DPSCs.
Our data demonstrate that HS is an appropriate supplement for
the in vitro expansion of human DPSCs, as its addition to culture
medium promotes a good proliferation rate comparable to the one
measured in culture conditions using FCS. Furthermore, HS
increases the hDPSCs doubling during culture indicating this as an
the optimal condition to obtain sufficient cell number soon and
consequently to reduce the waiting for a therapeutical treatment.
Otherwise, cells cultured in serum free medium were growth
arrested. Moreover HS does not induce cell senescence or
apoptosis and does not affect the surface antigens expression and
the multi-lineage differentiation ability of hDPSCs.
The expression of bone related proteins as well as the
mineralization of the extracellular matrix analyzed in in vitro
osteogenic differentiation experiments indicate that the use of HS
is adequate to hDPSCs osteogenic differentiation protocols.
Moreover HS, respect to FCS, seems to induce a better
mineralization of extracellular matrix synthesized by differentiat-
ing hDPSCs.
When transplanted in vivo, in immunocompromised animals, by
means of stem cell-scaffold constructs, hDPSCs pre-differentiated
in both the osteogenic media show a significant contribution to the
regeneration of critical size bone defect. Immunofluorescence
staining with anti-human mitochondria antibody demonstrates
that hDPSCs widely contribute to the osteocyte population of the
Figure 5. Confocal images of implants pre-differentiated in both the conditions. A–D: Double fluorescence signals from DAPI (blue) and
anti-hMit Ab (green) superimposed to pseudo-phase contrast images (B, D). Arrowheads indicate cells entrapped in calcified bone matrix clearly
stained by anti-human mitochondria antibody. E–H: triple fluorescence signals from DAPI (blue) and anti-hMit (green) and anti-OCN (red) Abs
superimposed to pseudo-phase contrast images (F, H). Yellow arrowheads indicate osteocytes labelled by the two Abs; cyan arrowheads indicate
OCN deposits in extracelluar bone matrix. I–L: triple fluorescence signals from DAPI (blue) and anti-hMit (green) and anti-von Willebrand factor (red)
Abs superimposed to pseudo-phase contrast images (J, L). Arrowheads indicate vasa double stained by the two Abs. Bar: 10 mm.
doi:10.1371/journal.pone.0050542.g005
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new-formed bone and seem to participate to the angiogenetic
process that gives rise to endothelial cells of the new-formed bone.
Thus, in our study we have demonstrated that human serum
represents an eligible alternative to FCS, for successfully expand-
ing and differentiating human DPSCs towards osteogenic lineage,
finding, furthermore, a helpful application for in vivo transplanta-
tion. The results we have obtained in vivo allow to propose human
serum as additive for expansion and differentiation of hDPSCs to
be applied in human cell therapy with GMP-compatible protocols.
Indeed, it matches with the criteria approved by the Committee
for medicinal products for human use.
Supporting Information
Figure S1 A–B: DAPI/anti-hMit immunofluorescence staining
on control implant (only collagen sponge). C: immunohistochem-
ical staining with anti-hMit Ab on section from implants pre-
differentiated with HS. Black arrowheads indicate cells positive to
anti-hMit Ab. Red arrowhead indicates vasa with endothelium
stained by anti-hMit Ab. D: control; immunoperoxidase was
carried out without primary Ab. E: Spectral image of immuno-
fluorescence staining on control implant not containing human
cells. Image was acquired on the same field of fig. A–B. ROI
indicates areas of spectral emission analysis of DAPI and Alexa488
fluorochromes, reported with same color in the graphs on the right
side. E1 shows theoretical emission spectra of DAPI superimposed
to DAPI emission from sample. E2 represents emission of
Alexa488 from sample superimposed on their theoretical spec-
trum.F: Spectral image of immunofluorescence staining with anti-
hMit Ab counterstained with DAPI. ROI indicates areas of
spectral emission analysis of DAPI and Alexa488 fluorochromes,
reported with same color in the graphs on the right side. In the
graphs are reported theoretical emission spectra of DAPI and
Alexa488 superimposed to the emission of: DAPI from sample
(E1), Alexa488 from sample (E2). Signals from DAPI and
Alexa488 match with respective theoretical spectra. G: Spectral
image of double immunofluorescence staining with anti-hMit and
anti-OCN Abs. ROI indicated areas of spectral emission analysis
reported with same color in the graphs on the right side. In the
graphs were reported theoretical emission spectra of Alexa488 and
Alexa546 superimposed to the emission of Alexa488, Alexa546.
G1 represents the emission of double signal from a cell double
labelled by anti-hMit and anti-OCN Abs revealed by Alexa488
and Alexa546 respectively. G2 describes the spectral emission of
the area containing OCN extracellular deposits that emit a signal
matching with Alexa546 theoretical spectrum. H: spectral image
of signals from anti-hMit (green) and anti-von Willebrand factor
(red). ROI in the image represents areas analyzed in the graphs on
the right side. Corresponding spectra are shown in the same color
of ROI. H1 represents emission spectra of area labelled with anti-
hMit and anti-von Willebrand factor Abs revealed by Alexa488
and Alexa546 respectively. Emission spectrum from sample
presents two peaks overlapping the theoretical spectra of both
Alexa488 and Alexa546. Arrows on the top of all graphs indicate
the wavelengths of laser lines used to excite the respective
fluorochromes. In correspondence of the excitation laser wave-
length the emission spectra show an unreal trend to zero since the
correspondent line of the spectral detector was automatically
turned off in order to avoid photomultiplier damages. Images
show implants of hDPSCs pre-differentiated with HS-medium.
The same results were obtained with FCS-medium (data not
shown). th: theoretical; Alx: Alexa.
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